Abstract
Background Veno-arterial Extracorporeal Membrane Oxygenation (VA-ECMO) is a rapidly expanding therapy with a relatively limited evidence base. Due to both quantitative and qualitative acquired coagulopathies in VA-ECMO, bleeding remains a major complication and with potentially catastrophic outcomes. Simultaneously, coagulation activation occurs via blood contact with the extracorporeal circuit, which risks not only vital organ emboli, but also the circuit viability. This carries the risk of equally catastrophic complications. As such, VA-ECMO patients are routinely anticoagulated. A large variation in practice exists surrounding anticoagulation in VA-ECMO. Despite an increasing uptake in the therapy, the evidence base is limited and current guidelines surrounding anticoagulation practice are based on expert opinion. We will perform a study level systematic review and meta-analysis of VA-ECMO patients comparing anticoagulation strategies, including the agent of anticoagulation, the method of monitoring and the targeted degree of anticoagulation to assess the association between described anticoagulation strategies and bleeding and thrombotic complications.
Methods We will perform a study level meta-analysis of randomised controlled trials (RCTs) and cohort studies that report on bleeding and thrombotic complications in VA-ECMO. Our primary objective is to describe the incidence of bleeding and thrombotic complications associated with individual anticoagulation strategies. In order to be included, a study must report the anticoagulant drug used, the method of monitoring used, or the anticoagulation target used, and at least one outcome of interest. Four databases will be systematically reviewed by two authors. Two authors will extract and assess for risk of bias using the Cochrane Risk of Bias tool for RCTs and the ROBINS-I tool for observational studies. Data will be analysed via incidence rates of bleeding and thrombotic complications, with a subgroup analysis of each anticoagulation strategy where able. The study will be reported in line with PRISMA guidelines.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This study did not receive any funding
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
This manuscript is a protocol for a systematic review
